Literature DB >> 21592570

PRAME: from diagnostic marker and tumor antigen to promising target of RNAi therapy in leukemic cells.

Bu Yin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21592570     DOI： 10.1016/j.leukres.2011.04.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  2 in total

1.  Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.

Authors:  Amy B Hont; C Russell Cruz; Robert Ulrey; Barbara O'Brien; Maja Stanojevic; Anushree Datar; Shuroug Albihani; Devin Saunders; Ryo Hanajiri; Karuna Panchapakesan; Sam Darko; Payal Banerjee; Maria Fernanda Fortiz; Fahmida Hoq; Haili Lang; Yunfei Wang; Patrick J Hanley; Jeffrey S Dome; Catherine M Bollard; Holly J Meany
Journal:  J Clin Oncol       Date:  2019-07-29       Impact factor: 44.544

2.  Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.

Authors:  Maja Stanojevic; Amy B Hont; Ashley Geiger; Samuel O'Brien; Robert Ulrey; Melanie Grant; Anushree Datar; Ping-Hsien Lee; Haili Lang; Conrad R Y Cruz; Patrick J Hanley; A John Barrett; Michael D Keller; Catherine M Bollard
Journal:  Cytotherapy       Date:  2021-04-05       Impact factor: 6.196
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.